GO category analysis and KEGG pathway analysis in the TCR signature gene set
| Analytical tool . | Gene no. . | Gene . | P . |
|---|---|---|---|
| GO category | |||
| γδTCL | |||
| Cellular defense response | 5 | KIR2DL4, NCR1, C3AR1, KLRC2, KLRC4 | 1.17 × 10−4 |
| Signal transduction activity | 29 | KLRD1, ANXA9, FNDC3B, GPR37, KIR2DL4, MARCO, EDG7, NCR1, MS4A5, HPGD, FCGR3A, LGR4, FCRLB, C3AR1, CXCL12, RTN4R, PAQR9, KLRC2, GPR153, FCGR3B, KIR2DL2, EDG8, ADRB1, CD36, FZD5, SCARF2, KIR3DL1, EPHA6, KLRC4 | 5.09 × 10−6 |
| Receptor activity | 28 | GPR37, KIR2DL4, ANXA9, KLRD1, FNDC3B, EDG7, HPGD, MARCO, LGR4, MS4A5, FCGR3A, NCR1, C3AR1, FCRLB, KLRC2, PAQR9, RTN4R, GPR153, EDG8, FCGR3B, KIR2DL2, ADRB1, FZD5, CD36, SCARF2, KIR3DL1, EPHA6, KLRC4 | 7.10 × 10−8 |
| Transmembrane receptor activity | 16 | ANXA9, GPR37, KIR2DL4, KLRD1, LGR4, HPGD, MARCO, EDG7, C3AR1, KLRC2, EDG8, GPR153, ADRB1, FZD5, EPHA6, KIR3DL1 | 4.46 × 10−4 |
| IgG binding | 2 | FCGR3A, FCGR3B | 3.07 × 10−4 |
| αβTCL | |||
| Organismal physiologic process | 14 | UBD, CXCL13, COL4A4, CCL18, KCNE2, CCL17, C3, TMEM142A, DLL4, APOE, COL4A3, TNFRSF25, MMP9, CCL19 | 3.24 × 10−4 |
| Regulation of organismal physiologic process | 4 | COL4A4, KCNE2, C3, APOE | 5.87 × 10−4 |
| Circulation | 4 | KCNE2, DLL4, COL4A3, APOE | 3.14 × 10−4 |
| Regulation of neurophysiologic process | 2 | COL4A4, APOE | 7.55 × 10−4 |
| Regulation of transmission of nerve impulse | 2 | COL4A4, APOE | 7.55 × 10−4 |
| Regulation of synapse structure and function | 2 | COL4A4, APOE | 8.69 × 10−4 |
| Regulation of synaptic transmission | 2 | COL4A4, APOE | 7.55 × 10−4 |
| Inflammatory response | 5 | CXCL13, CCL18, CCL17, C3, CCL19 | 6.05 × 10−4 |
| Behavior | 5 | CCL18, CXCL13, CCL17, APOE, CCL19 | 2.47 ×10−4 |
| Locomotory behavior | 4 | CXCL13, CCL18, CCL17, CCL19 | 4.92 × 10−4 |
| Taxis | 4 | CXCL13, CCL18, CCL17, CCL19 | 4.22 × 10−4 |
| Chemotaxis | 4 | CXCL13, CCL18, CCL17, CCL19 | 4.22 × 10−4 |
| Receptor binding | 9 | ADAMDEC1, CCL18, CXCL13, CCL17, C3, DLL4, APOE, COL4A3, CCL19 | 2.76 × 10−5 |
| G-protein–coupled receptor binding | 4 | CCL18, CXCL13, CCL17, CCL19 | 1.57 × 10−5 |
| Chemokine receptor binding | 4 | CCL18, CXCL13, CCL17, CCL19 | 6.97 × 10−6 |
| Chemokine activity | 4 | CCL18, CXCL13, CCL17, CCL19 | 6.37 × 10−6 |
| Extracellular region | 11 | CCL18, COL4A4, CXCL13, CCL17, C3, WNT5B, MMP9, COL4A3, APOE, SPOCK2, CCL19 | 7.97 × 10−5 |
| Extracellular region part | 9 | CCL18, COL4A4, CXCL13, CCL17, SPOCK2, APOE, COL4A3, MMP9, CCL19 | 7.33 × 10−5 |
| Sheet-forming collagen | 2 | COL4A4, COL4A3 | 1.70 × 10−4 |
| Collagen type IV | 2 | COL4A4, COL4A3 | 1.21 × 10−4 |
| KEGG pathway | |||
| γδTCL | |||
| Natural killer cell–mediated cytotoxicity | 5 | FCGR3A, KIR3DL1, KLRC2, KLRD1, NCR1 | 8.10 × 10−4 |
| Antigen processing and presentation | 4 | KIR3DL1, KLRC2, KLRD1, KLRC4 | 7.53 × 10−4 |
| Atrazine degradation | 2 | APOBEC3A, APOBEC3B | 4.42 × 10−4 |
| αβTCL | |||
| Cytokine–cytokine receptor interaction | 5 | CXCL13, CCL17, CCL18, CCL19, TNFRSF25 | 2.65 × 10−4 |
| Analytical tool . | Gene no. . | Gene . | P . |
|---|---|---|---|
| GO category | |||
| γδTCL | |||
| Cellular defense response | 5 | KIR2DL4, NCR1, C3AR1, KLRC2, KLRC4 | 1.17 × 10−4 |
| Signal transduction activity | 29 | KLRD1, ANXA9, FNDC3B, GPR37, KIR2DL4, MARCO, EDG7, NCR1, MS4A5, HPGD, FCGR3A, LGR4, FCRLB, C3AR1, CXCL12, RTN4R, PAQR9, KLRC2, GPR153, FCGR3B, KIR2DL2, EDG8, ADRB1, CD36, FZD5, SCARF2, KIR3DL1, EPHA6, KLRC4 | 5.09 × 10−6 |
| Receptor activity | 28 | GPR37, KIR2DL4, ANXA9, KLRD1, FNDC3B, EDG7, HPGD, MARCO, LGR4, MS4A5, FCGR3A, NCR1, C3AR1, FCRLB, KLRC2, PAQR9, RTN4R, GPR153, EDG8, FCGR3B, KIR2DL2, ADRB1, FZD5, CD36, SCARF2, KIR3DL1, EPHA6, KLRC4 | 7.10 × 10−8 |
| Transmembrane receptor activity | 16 | ANXA9, GPR37, KIR2DL4, KLRD1, LGR4, HPGD, MARCO, EDG7, C3AR1, KLRC2, EDG8, GPR153, ADRB1, FZD5, EPHA6, KIR3DL1 | 4.46 × 10−4 |
| IgG binding | 2 | FCGR3A, FCGR3B | 3.07 × 10−4 |
| αβTCL | |||
| Organismal physiologic process | 14 | UBD, CXCL13, COL4A4, CCL18, KCNE2, CCL17, C3, TMEM142A, DLL4, APOE, COL4A3, TNFRSF25, MMP9, CCL19 | 3.24 × 10−4 |
| Regulation of organismal physiologic process | 4 | COL4A4, KCNE2, C3, APOE | 5.87 × 10−4 |
| Circulation | 4 | KCNE2, DLL4, COL4A3, APOE | 3.14 × 10−4 |
| Regulation of neurophysiologic process | 2 | COL4A4, APOE | 7.55 × 10−4 |
| Regulation of transmission of nerve impulse | 2 | COL4A4, APOE | 7.55 × 10−4 |
| Regulation of synapse structure and function | 2 | COL4A4, APOE | 8.69 × 10−4 |
| Regulation of synaptic transmission | 2 | COL4A4, APOE | 7.55 × 10−4 |
| Inflammatory response | 5 | CXCL13, CCL18, CCL17, C3, CCL19 | 6.05 × 10−4 |
| Behavior | 5 | CCL18, CXCL13, CCL17, APOE, CCL19 | 2.47 ×10−4 |
| Locomotory behavior | 4 | CXCL13, CCL18, CCL17, CCL19 | 4.92 × 10−4 |
| Taxis | 4 | CXCL13, CCL18, CCL17, CCL19 | 4.22 × 10−4 |
| Chemotaxis | 4 | CXCL13, CCL18, CCL17, CCL19 | 4.22 × 10−4 |
| Receptor binding | 9 | ADAMDEC1, CCL18, CXCL13, CCL17, C3, DLL4, APOE, COL4A3, CCL19 | 2.76 × 10−5 |
| G-protein–coupled receptor binding | 4 | CCL18, CXCL13, CCL17, CCL19 | 1.57 × 10−5 |
| Chemokine receptor binding | 4 | CCL18, CXCL13, CCL17, CCL19 | 6.97 × 10−6 |
| Chemokine activity | 4 | CCL18, CXCL13, CCL17, CCL19 | 6.37 × 10−6 |
| Extracellular region | 11 | CCL18, COL4A4, CXCL13, CCL17, C3, WNT5B, MMP9, COL4A3, APOE, SPOCK2, CCL19 | 7.97 × 10−5 |
| Extracellular region part | 9 | CCL18, COL4A4, CXCL13, CCL17, SPOCK2, APOE, COL4A3, MMP9, CCL19 | 7.33 × 10−5 |
| Sheet-forming collagen | 2 | COL4A4, COL4A3 | 1.70 × 10−4 |
| Collagen type IV | 2 | COL4A4, COL4A3 | 1.21 × 10−4 |
| KEGG pathway | |||
| γδTCL | |||
| Natural killer cell–mediated cytotoxicity | 5 | FCGR3A, KIR3DL1, KLRC2, KLRD1, NCR1 | 8.10 × 10−4 |
| Antigen processing and presentation | 4 | KIR3DL1, KLRC2, KLRD1, KLRC4 | 7.53 × 10−4 |
| Atrazine degradation | 2 | APOBEC3A, APOBEC3B | 4.42 × 10−4 |
| αβTCL | |||
| Cytokine–cytokine receptor interaction | 5 | CXCL13, CCL17, CCL18, CCL19, TNFRSF25 | 2.65 × 10−4 |